NUTROPIN AQ NUSPIN
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUTROPIN AQ NUSPIN is a recombinant human growth hormone (somatropin) administered via injection for growth hormone deficiency and related disorders. The mechanism involves binding to growth hormone receptors to promote linear growth, metabolic effects, and body composition changes. It is a long-established biologic therapy approved nearly 30 years ago.
$6MPart D
LOE ApproachingModest Part D footprint with LOE approaching signals a mature, stable franchise facing patent expiration and biosimilar competition in the near term.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NUTROPIN AQ NUSPIN offers experience in late-stage product lifecycle management, biosimilar defense, and managed care negotiations in a mature therapeutic area. Career growth is focused on defensive commercial strategy and stakeholder retention rather than new market expansion.
Brand ManagerMedical Science Liaison
Worked on NUTROPIN AQ NUSPIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.